以军事斗争卫勤准备为牵引 努力提高海上医疗救护能力

作者总结了医院开展海上卫勤战备训练的做法，在针对海上医疗救护的使命任务不断增强做好卫勤准备的责任感，紧扣海上医疗救护平台的特殊要求努力提高医院船医疗队救治能力，突破海上医疗救护技术的瓶颈制约积极开展海战伤救治技术及应用研究等方面，取得了明显效果。     

"11.24"海难援救军人的心理健康状况分析

目的 探讨海难后军队应激援救人员的心理健康特点，为建立特定人群的心理健康评定体系提供科学依据。方法 采用症状自评量表和自行编制的调查表对39名1999－11－24烟台“大禹”海难1mo后的善后援救军人进行了心理健康测试，并将调查结果与对照军人和国内军人常模进行了比较。结果 接受调查的应激人群的SCL－90总分79.5%（31／39）的人评定为正常，总分≥160分为8例，占20.5%。SCL－90总分、射体化、焦虑、恐怖与精神病性因子与国内军人常模比较无显差异，但阳性项目数、强迫症状、人际敏感、抑郁、敌对及偏执因子分均显低于国内军人常模（P＜0.05-0.01）；而阳性症状均分显高于国内军人常模（P＜0.05）。应激人群的阳性项目数明显低于对照人群，而阳性症状的痛苦水平明显高于对照人群（P＜0.01）；阳性症状均分仍显高于对照人群（P＜0.05）。结论 提示受调查的应激人群的阳性症状均分显高于国内军人常模，改善婚姻状况和与同胸关系、完善上级领导工作方法和善后处理可以改善SCL－90结果，减少生活事件的刺激量可望改善其心理健康状况。     

城市医疗救治体系在应对公共卫生事件中的管理实践与思考

医疗救治体系是公共卫生体系建设的重要组成部分 ,建立和完善医疗救治体系对于提高收治率、降低病死率 ,缓解公共卫生危机具有直接而关键的作用。该文总结回顾了上海在防治SARS期间医疗救治工作的组织与管理 ,简要介绍了上海构建突发公共卫生事件医疗救治体系的基本思路     

移动医院的创建及其在国际救援中的应用

2004年底苏门答腊岛近海发生9级地震和人类历史上最严重的海啸,中国参加了国际救援活动.中国国际救援队创建了移动医院,在亚齐省班达亚齐市实施救援.移动医院的编制为26名医务人员,下分指挥组、分类检伤组、现场救治组、外科救治组、内科救治组、医技组、留观后送组.展开后占地约200平方米.开展了巡诊、院内救治、卫生防疫、灾后医院重建,及培训灾区当地医务人员等工作.总结出如下经验:应加强战役后方,应将所有信息数字化,培训复合型人才十分重要.移动医院是救援队实施救援的重要手段和有效方式,尤其在重大灾害中抢救危重伤员时可发挥重要作用.     

Post‐traumatic reactions among rescue personnel 96 hours after the Hilton Hotel bombing in Sinai: The effect of previous exposure

This paper considers the immediate post‐traumatic reactions of rescue personnel who were exposed to the Hilton Hotel bombing in Sinai. The entire rescue personnel (n = 26) were assessed and separated into two groups on the basis of previous exposure to the same type of trauma. The results suggest that among rescue personnel, those with previous exposure had a lower level of post‐traumatic symptoms than those who were being exposed for the first time. This supports the hypothesis that previous exposure to the same type of trauma has an immunizing effect for subsequent same type of traumatic event among rescue personnel. Copyright © 2005 John Wiley & Sons, Ltd.     

Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma

Summary The effect of leucovorin (LV) given in various doses and schedules on the in vivo antitumor activity and toxicity of 5-fluorouracil (5FU) was studied in two murine colon cancer lines, i.e., Colon 26 (relatively resistant to 5FU) and Colon 38 (5FU sensitive), maintained in Balb-c and C57B1/6 mice, respectively. Mice were treated weekly with 5FU at the maximum tolerated dose, alone and in combination with LV. In Colon 26, neither simultaneous administration of 5FU and LV nor 5FU combined with delayed administration of LV potentiated the antitumor activity of 5FU. LV given twice — 1 hr before (50 mg/kg) and then together (50 mg/kg) with 5FU (100 mg/kg) — gave significantly better delay of tumor growth of both tumor lines than 5FU did alone (100 mg/kg). No differences were found after a total LV dose of 100 or 200 mg/kg. Delayed administration of uridine (3500 mg/kg) allowed the use of higher 5FU doses, which improved the antitumor effect on Colon 26. Systemic toxicity led to moderate weight loss in treated mice, but was comparable for mice treated with 5FU alone or combined with LV. Hematological toxicity consisted of moderate leukopenia (nadir 40%), which was observed with the most active schedule and was less severe than with 5FU alone. This schedule did not cause thrombocytopenia, but after discontinuation the thrombocyte count showed an overshoot. Addition of uridine to this schedule reduced hematological toxicity only slightly. It is concluded that LV potentiated the antitumor activity of 5FU against two solid tumor lines, i.e., a relatively resistant and a sensitive murine colon carcinoma, and that toxicity was moderate.Abbreviations 5FU 5-fluorouracil - LV leucovorin (folinic acid, 5-formyl-tetrahydrofolate) - FdUMP 5-fluoro 2-deoxyuridine 5monophosphate - TS thymidylate synthase - CH2-THF 5-10 methylenetetrahydrofolate - UR uridine - GDF growth delay factor - TD tumor doubling time - MTD maximum tolerated dose - T/C mean tumor volume of treated mice divided by mean tumor volume of control mice     

Rescue ICSI of oocytes that failed to extrude the second polar body 6 h post-insemination in conventional IVF

BACKGROUND: Attempts to 'rescue' by ICSI oocytes that remained unfertilized 24 h after conventional IVF have generally resulted in poor outcomes. The aim of the present study was to compare the outcome of rescue ICSI performed on one group of patients 6 h after initial insemination with those of another group where rescue ICSI was performed 22 h after initial insemination. METHODS: Twenty-five patient IVF cycles provided the oocytes for rescue ICSI 6 h after initial insemination, and 20 cycles provided the oocytes for rescue ICSI 22 h after initial insemination in this retrospective study. Fertilization and cleavage rates, embryo quality, implantation, and pregnancy rates after rescue ICSI were the main outcome measures. RESULTS: A fertilization rate of 70.3% was achieved with 6 h rescue ICSI compared with 48.5% with 22 h rescue ICSI (P < 0.0001). From 6 h rescue ICSI, 12 clinical pregnancies (48.0%) resulted in three sets of twins, eight singletons and one abortion. From 22 h rescue ICSI there was one (5.0%) singleton pregnancy and delivery of a healthy baby. Likewise, the implantation rate was 20.2% from 6 h rescue ICSI compared with 1.72% from 22 h rescue ICSI (P < 0.02). CONCLUSIONS: Rescue ICSI after 6 h post-insemination (46 h post-HCG) gave better fertilization, pregnancy and implantation rates compared with rescue ICSI after 22 h when oocytes have become aged.     

Acute optic neuritis: a virological study in relation to multiple sclerosis.

Previous ultrastructural examination of peripheral blood lymphocytes revealed the presence of intranuclear filamentous structures in multiple sclerosis (MS) and in some optic neuritis (ON) patients. The present investigation was undertaken in the attempt to correlate the presence of such structures with the etiology of ON and MS and possibly to demonstrate the viral origin of the filaments. Suitable virological and serological techniques were used to detect and isolate infectious agents from peripheral blood samples and body excretions of 12 monosymptomatic ON patients at their first acute attack. Nevertheless, any efforts to demonstrate the presence of a virus in these patients have been unsuccessful: no evidence of active viral infection was obtained by serological studies of serum and cerebrospinal fluid samples, nor could viral antigens or inclusions be observed by immunofluorescence and cytochemical analysis. Negative results were also obtained from studies performed in parallel on MS patients and various controls. The significance of the failure to isolate infectious agents from either ON and MS patients is discussed.     

Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept

Belatacept may increase cytomegalovirus (CMV) disease risk after conversion from CNI-based therapy. We analyzed CMV disease characteristics after belatacept conversion. Propensity score matching was used to compare CMV disease incidence in belatacept- and CNI-treated kidney transplant recipients (KTRs). CMV disease characteristics and risk factors under belatacept were analyzed. In total, 223 KTRs (median age [IQR] 59.2 years [45.4–68.5]) were converted to belatacept (median of 11.5 months [2.5–37.0] post-transplantation); 40/223 (17.9%) developed CMV disease. Independent risk factors included increased age (p = .0164), D+/R− CMV serostatus (p = .0220), and low eGFR at conversion (p = .0355). Among 181 belatacept-treated patients matched to 181 controls, 32/181 (17.7%) experienced CMV disease (vs. 5/181 controls [2.8%]). CMV disease cumulative incidences were 6.33 and 0.91/100 person-years (p-y) in belatacept and control groups, respectively. CMV disease risk was particularly high in elderly patients (converted >70 years) and those with eGFR <30 ml/min; cumulative incidences were 18.4 and 5.2/100 p-y, respectively. CMV diseases under belatacept were atypical, with late-onset disease (24/40 patients [60%]), high CMV seropositivity (27/40, 67%), increased severe and tissue-invasive disease rates (gastrointestinal involvement in 32/40 [80%]) and life-threatening diseases (4/40 [10%]). These findings should stimulate further research to secure the use of belatacept as a valuable rescue therapy in KTRs.